CTN-0028-A-1: Does Methylphenidate Treatment for ADHD Increase the Rate of Smoking in Adolescents with Comorbid ADHD, SUD, and Nicotine Dependence?
Kevin M. Gray, MD
Medical University of South Carolina
Dept. of Psychiatry & Behavioral Sciences
The purpose of this study was to measure any change in the rate of cigarette smoking among participants in the CTN-0028 (at the LRADAC site only). The hypothesis is that OROS-MPH treatment for ADHD among adolescents with comorbid ADHD, SUD, and nicotine dependence will not increase the rate of cigarette smoking. The study will compare self-reported smoking rate and urine cotinine semi-quantitative levels in adolescents receiving OROS-MPH vs. those receiving placebo to test the hypothesis above.
Baseline (pre-treatment) cigarette smoking was positively correlated with cannabis use. Negligible decline in cigarette smoking during treatment for non-nicotine SUD was observed in both medication groups. Regular cigarette and cannabis users at baseline who reduced their cannabis use by >50% also reduced cigarette smoking.
Results Article: Gray KM, Riggs PD, Min SJ,et al. Cigarette and Cannabis Use Trajectories among Adolescents in Treatment for Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders. Drug and Alcohol Dependence 2011;117(2-3):242-247. [get article]
- CTN-0028: Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents with Substance Use Disorders
All Participating Nodes: